Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

Core Insights - Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing precisely targeted therapies for cancer, specifically targeting clinically proven kinase targets [3]. Group 1: Company Overview - Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer [3]. - The company leverages deep expertise in chemistry and structure-based drug design to create innovative small molecules that aim to overcome resistance and minimize adverse events [3]. Group 2: Upcoming Events - James Porter, Ph.D., CEO, and Alexandra Balcom, CFO, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. ET [1]. - A live webcast of the event will be available on the company's website and archived for 30 days following the presentation [2].